Could see very strong third quarter for Aurobindo Pharma: Miintdirect.com

In a chat with ET Now, Avinnash Gorakssakar, Head of Research, Miintdirect.com, shares his views on Aurobindo Pharma. Excerpt:

ET Now: What is your view on the price movement that we have seen on Aurobindo Pharma?

Avinnash Gorakssakar: As far as Aurobindo is concerned, my guess is this is clearly a classic play on the US market. They have got all the regulatory approvals in place and very clearly despite the outperformance, I would not be surprised that we could see a very strong third quarter which is expected now in January.

Hence, clearly some more short term upside could come in. Although the stock has run up, the valuations still look relatively cheap if you compare it to the other larger players like a Lupin or Sun or maybe a Ranbaxy and where earnings growth is going to drive the stock price further upside.